Form 4: Chimerix Director Marc D. Kozin Reports Acquisition of Stock Options

Director Marc D. Kozin reports acquisition of 100,000 Chimerix stock options.

Summary

• On March 20, 2024, Marc D. Kozin, a director of Chimerix Inc., acquired 100,000 stock options.
• The exercise price of these options is $0.99.
• One-third of the shares will vest on March 20, 2025, with the remainder vesting in 24 equal monthly installments, fully vesting on March 20, 2027, subject to continuous service.
• The options will fully vest upon a Change in Control.
• Following the transaction, Kozin beneficially owns 100,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing about stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule incentivizes long-term commitment from the director.

Future Outlook

The vesting schedule suggests an expectation of continued service and potential value creation over the next few years.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule described is fairly standard, with vesting periods often spanning several years to incentivize long-term commitment.
• The specific terms of the option grant (exercise price, vesting schedule, etc.) would need to be compared to those of similar companies (e.g., BioCryst Pharmaceuticals, Gilead Sciences) to determine if they are in line with industry norms.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates